Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA
Despite being an uncommon disease, the high mortality rate and severe long-term consequences of IMD result in a substantial economic impact. Comprehensive market and non-market productivity losses for both patients and caregivers should be considered when evaluating and communicating the true burden of IMD.
Authors
- Hiral Shah (ORCID: https://orcid.org/0000-0003-0204-451X)
- Oscar Herrera-Restrepo (ORCID: https://orcid.org/0000-0001-8193-999X)
- Mei Grace (ORCID: https://orcid.org/0009-0008-3862-8203)
- Elise J. Kuylen (ORCID: https://orcid.org/0000-0002-3528-5507)
- Frederik Verelst (ORCID: https://orcid.org/0000-0001-8399-743X)
- Shah Alam Khan (ORCID: https://orcid.org/0000-0001-5121-8630)
- Shahina Begum (ORCID: https://orcid.org/0000-0002-3521-8865)
- James E. Graham (ORCID: https://orcid.org/0000-0002-3227-5928)
- Zeki Kocaata (ORCID: https://orcid.org/0000-0002-5231-3389)
- Ginita Jutlla (ORCID: https://orcid.org/0000-0001-6065-8574)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (United States) (US)
- RTI Health Solutions (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- GlaxoSmithKline (Germany) (DE)
- Diagnostics for the Real World (United Kingdom) (GB)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1007/s40273-025-01477-0
- Citations
- 1
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 1.18